

Andrei V Gudkov

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8401021/andrei-v-gudkov-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

186
papers

14,011
citations

67
h-index

115
g-index

198
ext. papers

15,558
ext. citations

8.4
avg, IF

6.09
L-index

#	Paper	IF	Citations
186	Alkaloid-rich fraction of <i>Ervatamia coronaria</i> sensitizes colorectal cancer through modulating AMPK and mTOR signalling pathways. <i>Journal of Ethnopharmacology</i> , 2022 , 283, 114666	5	2
185	A deimmunized and pharmacologically optimized Toll-like receptor 5 agonist for therapeutic applications. <i>Communications Biology</i> , 2021 , 4, 466	6.7	2
184	Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG. <i>Cell Reports</i> , 2021 , 35, 108994	10.6	4
183	Resistance of bone marrow stroma to genotoxic preconditioning is determined by p53. <i>Cell Death and Disease</i> , 2021 , 12, 545	9.8	
182	Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma. <i>Clinical Cancer Research</i> , 2021 , 27, 4338-4352	12.9	0
181	Longitudinal analysis of blood markers reveals progressive loss of resilience and predicts human lifespan limit. <i>Nature Communications</i> , 2021 , 12, 2765	17.4	17
180	Stimulation of an anti-tumor immune response with "chromatin-damaging" therapy. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 70, 2073-2086	7.4	3
179	Induction of monoamine oxidase A-mediated oxidative stress and impairment of NRF2-antioxidant defence response by polyphenol-rich fraction of <i>Bergenia ligulata</i> sensitizes prostate cancer cells in vitro and in vivo. <i>Free Radical Biology and Medicine</i> , 2021 , 172, 136-151	7.8	5
178	Development of infrastructure for a systemic multidisciplinary approach to study aging in retired sled dogs. <i>Aging</i> , 2021 , 13, 21814-21837	5.6	2
177	Signaling through TLR5 mitigates lethal radiation damage by neutrophil-dependent release of MMP-9. <i>Cell Death Discovery</i> , 2021 , 7, 266	6.9	0
176	TLR5 agonist entolimod reduces the adverse toxicity of TNF while preserving its antitumor effects. <i>PLoS ONE</i> , 2020 , 15, e0227940	3.7	10
175	First-in-human study of anticancer immunotherapy drug candidate mobilan: safety, pharmacokinetics and pharmacodynamics in prostate cancer patients. <i>Oncotarget</i> , 2020 , 11, 1273-1288	3.3	3
174	Superior cancer preventive efficacy of low versus high dose of mTOR inhibitor in a mouse model of prostate cancer. <i>Oncotarget</i> , 2020 , 11, 1373-1387	3.3	3
173	Effective targeting of NAMPT in patient-derived xenograft models of high-risk pediatric acute lymphoblastic leukemia. <i>Leukemia</i> , 2020 , 34, 1524-1539	10.7	9
172	OT-82, a novel anticancer drug candidate that targets the strong dependence of hematological malignancies on NAD biosynthesis. <i>Leukemia</i> , 2020 , 34, 1828-1839	10.7	13
171	Immune checkpoint protein VSIG4 as a biomarker of aging in murine adipose tissue. <i>Aging Cell</i> , 2020 , 19, e13219	9.9	7
170	Potent antileukemic activity of curaxin CBL0137 against MLL-rearranged leukemia. <i>International Journal of Cancer</i> , 2020 , 146, 1902-1916	7.5	13

169	TLR5 agonist entolimod reduces the adverse toxicity of TNF while preserving its antitumor effects 2020 , 15, e0227940		
168	TLR5 agonist entolimod reduces the adverse toxicity of TNF while preserving its antitumor effects 2020 , 15, e0227940		
167	TLR5 agonist entolimod reduces the adverse toxicity of TNF while preserving its antitumor effects 2020 , 15, e0227940		
166	TLR5 agonist entolimod reduces the adverse toxicity of TNF while preserving its antitumor effects 2020 , 15, e0227940		
165	A novel small molecule that kills a subset of MLL-rearranged leukemia cells by inducing mitochondrial dysfunction. <i>Oncogene</i> , 2019 , 38, 3824-3842	9.2	12
164	Cells exhibiting strong promoter activation in vivo display features of senescence. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 2603-2611	11.5	108
163	LINE1 Derepression in Aged Wild-Type and SIRT6-Deficient Mice Drives Inflammation. <i>Cell Metabolism</i> , 2019 , 29, 871-885.e5	24.6	138
162	Latest advances in aging research and drug discovery. <i>Aging</i> , 2019 , 11, 9971-9981	5.6	6
161	Quantitative characterization of biological age and frailty based on locomotor activity records. <i>Aging</i> , 2018 , 10, 2973-2990	5.6	20
160	TRAIN (Transcription of Repeats Activates INterferon) in response to chromatin destabilization induced by small molecules in mammalian cells. <i>ELife</i> , 2018 , 7,	8.9	19
159	Senescent cells expose and secrete an oxidized form of membrane-bound vimentin as revealed by a natural polyreactive antibody. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017 , 114, E1668-E1677	11.5	68
158	Mitigation of Radiation-Induced Epithelial Damage by the TLR5 Agonist Entolimod in a Mouse Model of Fractionated Head and Neck Irradiation. <i>Radiation Research</i> , 2017 , 187, 570-580	3.1	27
157	A review of the biomedical innovations for healthy longevity. <i>Aging</i> , 2017 , 9, 7-25	5.6	18
156	p16(Ink4a) and senescence-associated β -galactosidase can be induced in macrophages as part of a reversible response to physiological stimuli. <i>Aging</i> , 2017 , 9, 1867-1884	5.6	139
155	Murine mesenchymal cells that express elevated levels of the CDK inhibitor p16(Ink4a) in vivo are not necessarily senescent. <i>Cell Cycle</i> , 2017 , 16, 1526-1533	4.7	15
154	Novel mouse models of hepatic artery infusion. <i>Journal of Surgical Research</i> , 2017 , 219, 25-32	2.5	4
153	Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program. <i>Pediatric Blood and Cancer</i> , 2017 , 64, e26263	3	11
152	Physiological frailty index (PFI): quantitative in-life estimate of individual biological age in mice. <i>Aging</i> , 2017 , 9, 615-626	5.6	39

151	Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma. <i>Neuro-Oncology</i> , 2017 , 19, 186-196	1	30
150	p53 and the Carcinogenicity of Chronic Inflammation. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2016 , 6,	5.4	60
149	A murine model of targeted infusion for intracranial tumors. <i>Journal of Neuro-Oncology</i> , 2016 , 126, 37-45.	4.8	1
148	Toll-like receptor-5 agonist, entolimod, suppresses metastasis and induces immunity by stimulating an NK-dendritic-CD8+ T-cell axis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, E874-83	11.5	66
147	Aging of mice is associated with p16(Ink4a)- and β -galactosidase-positive macrophage accumulation that can be induced in young mice by senescent cells. <i>Aging</i> , 2016 , 8, 1294-315	5.6	185
146	CCI-007, a novel small molecule with cytotoxic activity against infant leukemia with MLL rearrangements. <i>Oncotarget</i> , 2016 , 7, 46067-46087	3.3	8
145	The Toll-like receptor 5 agonist entolimod suppresses hepatic metastases in a murine model of ocular melanoma via an NK cell-dependent mechanism. <i>Oncotarget</i> , 2016 , 7, 2936-50	3.3	33
144	Powerful Complex Immunoadjuvant Based on Synergistic Effect of Combined TLR4 and NOD2 Activation Significantly Enhances Magnitude of Humoral and Cellular Adaptive Immune Responses. <i>PLoS ONE</i> , 2016 , 11, e0155650	3.7	23
143	Preclinical Validation of a Single-Treatment Infusion Modality That Can Eradicate Extremity Melanomas. <i>Cancer Research</i> , 2016 , 76, 6620-6630	10.1	11
142	Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma. <i>Science Translational Medicine</i> , 2015 , 7, 312ra176	17.5	86
141	The Toll-Like Receptor 5 Agonist Entolimod Mitigates Lethal Acute Radiation Syndrome in Non-Human Primates. <i>PLoS ONE</i> , 2015 , 10, e0135388	3.7	36
140	Distinguishing the immunostimulatory properties of noncoding RNAs expressed in cancer cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, 15154-9	11.5	45
139	Small-molecule xenomycins inhibit all stages of the Plasmodium life cycle. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 1427-34	5.9	10
138	Functional Genomics and Computational Approaches Identify Novel Small Molecules Targeting Quiescent Leukemia Stem Cells. <i>Blood</i> , 2015 , 126, 1391-1391	2.2	
137	High-throughput screening identifies Ceefourin 1 and Ceefourin 2 as highly selective inhibitors of multidrug resistance protein 4 (MRP4). <i>Biochemical Pharmacology</i> , 2014 , 91, 97-108	6	41
136	Genome-wide adaptive complexes to underground stresses in blind mole rats <i>Spalax</i> . <i>Nature Communications</i> , 2014 , 5, 3966	17.4	101
135	Peptides genetically selected for NF- κ B activation cooperate with oncogene Ras and model carcinogenic role of inflammation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, E474-83	11.5	13
134	A flagellin-derived toll-like receptor 5 agonist stimulates cytotoxic lymphocyte-mediated tumor immunity. <i>PLoS ONE</i> , 2014 , 9, e85587	3.7	42

133	Toll-like receptor-5 agonist Entolimod broadens the therapeutic window of 5-fluorouracil by reducing its toxicity to normal tissues in mice. <i>Oncotarget</i> , 2014 , 5, 802-14	3.3	28
132	A purine nucleotide biosynthesis enzyme guanosine monophosphate reductase is a suppressor of melanoma invasion. <i>Cell Reports</i> , 2013 , 5, 493-507	10.6	29
131	Combined stimulation of Toll-like receptor 5 and NOD1 strongly potentiates activity of NF- κ B, resulting in enhanced innate immune reactions and resistance to Salmonella enterica serovar Typhimurium infection. <i>Infection and Immunity</i> , 2013 , 81, 3855-64	3.7	31
130	Central role of liver in anticancer and radioprotective activities of Toll-like receptor 5 agonist. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, E1857-66	11.5	93
129	p53 cooperates with DNA methylation and a suicidal interferon response to maintain epigenetic silencing of repeats and noncoding RNAs. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013 , 110, E89-98	11.5	168
128	Dysregulation of the mTOR pathway in p53-deficient mice. <i>Cancer Biology and Therapy</i> , 2013 , 14, 1182-84.6	4.6	24
127	Cell-based methods for the identification of MYC-inhibitory small molecules. <i>Methods in Molecular Biology</i> , 2013 , 1012, 255-64	1.4	
126	Cancer resistance in the blind mole rat is mediated by concerted necrotic cell death mechanism. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 19392-6	11.5	93
125	Toll-like receptor 5 agonist protects mice from dermatitis and oral mucositis caused by local radiation: implications for head-and-neck cancer radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012 , 83, 228-34	4	86
124	CBLB613: a TLR 2/6 agonist, natural lipopeptide of Mycoplasma arginini, as a novel radiation countermeasure. <i>Radiation Research</i> , 2012 , 177, 628-42	3.1	48
123	Identification of granulocyte colony-stimulating factor and interleukin-6 as candidate biomarkers of CBLB502 efficacy as a medical radiation countermeasure. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2012 , 343, 497-508	4.7	75
122	Hypoxia suppresses conversion from proliferative arrest to cellular senescence. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 13314-8	11.5	141
121	Targeting FACT complex suppresses mammary tumorigenesis in Her2/neu transgenic mice. <i>Cancer Prevention Research</i> , 2012 , 5, 1025-35	3.2	44
120	Structural basis of TLR5-flagellin recognition and signaling. <i>Science</i> , 2012 , 335, 859-64	33.3	356
119	Core circadian protein CLOCK is a positive regulator of NF- κ B-mediated transcription. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, E2457-65	11.5	215
118	A TLR5 agonist enhances CD8(+) T cell-mediated graft-versus-tumor effect without exacerbating graft-versus-host disease. <i>Journal of Immunology</i> , 2012 , 189, 4719-27	5.3	23
117	Prevention and mitigation of acute radiation syndrome in mice by synthetic lipopeptide agonists of Toll-like receptor 2 (TLR2). <i>PLoS ONE</i> , 2012 , 7, e33044	3.7	55
116	New nanoformulation of rapamycin Rapatar extends lifespan in homozygous p53 ^{-/-} mice by delaying carcinogenesis. <i>Aging</i> , 2012 , 4, 715-22	5.6	89

115	Rapamycin extends lifespan and delays tumorigenesis in heterozygous p53+/- mice. <i>Aging</i> , 2012 , 4, 709-146	5.6	114
114	Ribonucleotide reductase and thymidylate synthase or exogenous deoxyribonucleosides reduce DNA damage and senescence caused by C-MYC depletion. <i>Aging</i> , 2012 , 4, 917-22	5.6	22
113	Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib. <i>Oncotarget</i> , 2011 , 2, 209-21	3.3	78
112	Identification of low-molecular weight inhibitors of HIV-1 reverse transcriptase using a cell-based high-throughput screening system. <i>Antiviral Research</i> , 2011 , 91, 94-8	10.8	8
111	Curaxins: anticancer compounds that simultaneously suppress NF- κ B and activate p53 by targeting FACT. <i>Science Translational Medicine</i> , 2011 , 3, 95ra74	17.5	142
110	A TLR5 agonist inhibits acute renal ischemic failure. <i>Journal of Immunology</i> , 2011 , 187, 3831-9	5.3	32
109	Inflammation and p53: A Tale of Two Stresses. <i>Genes and Cancer</i> , 2011 , 2, 503-16	2.9	125
108	Histone methyltransferase KMT1A restrains entry of alveolar rhabdomyosarcoma cells into a myogenic differentiated state. <i>Cancer Research</i> , 2011 , 71, 3921-31	10.1	22
107	Elimination of proliferating cells unmasks the shift from senescence to quiescence caused by rapamycin. <i>PLoS ONE</i> , 2011 , 6, e26126	3.7	31
106	Association of <i>Mycoplasma hominis</i> infection with prostate cancer. <i>Oncotarget</i> , 2011 , 2, 289-97	3.3	81
105	Selenium is a modulator of circadian clock that protects mice from the toxicity of a chemotherapeutic drug via upregulation of the core clock protein, BMAL1. <i>Oncotarget</i> , 2011 , 2, 1279-90 ³⁻³	3.3	31
104	Inhibition of encephalomyocarditis virus and poliovirus replication by quinacrine: implications for the design and discovery of novel antiviral drugs. <i>Journal of Virology</i> , 2010 , 84, 9390-7	6.6	30
103	Regulation of NF- κ B by NSD1/FBXL11-dependent reversible lysine methylation of p65. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010 , 107, 46-51	11.5	207
102	A small molecule inhibitor of p53 stimulates amplification of hematopoietic stem cells but does not promote tumor development in mice. <i>Cell Cycle</i> , 2010 , 9, 1434-43	4.7	34
101	Weak p53 permits senescence during cell cycle arrest. <i>Cell Cycle</i> , 2010 , 9, 4323-7	4.7	116
100	Pathologies associated with the p53 response. <i>Cold Spring Harbor Perspectives in Biology</i> , 2010 , 2, a001180.2	180.2	88
99	Short-term inhibition of p53 combined with keratinocyte growth factor improves thymic epithelial cell recovery and enhances T-cell reconstitution after murine bone marrow transplantation. <i>Blood</i> , 2010 , 115, 1088-97	2.2	55
98	Paradoxical suppression of cellular senescence by p53. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010 , 107, 9660-4	11.5	236

97	Radioprotection: smart games with death. <i>Journal of Clinical Investigation</i> , 2010 , 120, 2270-3	15.9	51
96	Impact papers on aging in 2009. <i>Aging</i> , 2010 , 2, 111-21	5.6	29
95	The choice between p53-induced senescence and quiescence is determined in part by the mTOR pathway. <i>Aging</i> , 2010 , 2, 344-52	5.6	248
94	Validation-based insertional mutagenesis identifies lysine demethylase FBXL11 as a negative regulator of NFkappaB. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 16339-44	11.5	68
93	Pseudo-DNA damage response in senescent cells. <i>Cell Cycle</i> , 2009 , 8, 4112-8	4.7	173
92	Small molecule screening reveals a transcription-independent pro-survival function of androgen receptor in castration-resistant prostate cancer. <i>Cell Cycle</i> , 2009 , 8, 4155-67	4.7	14
91	Anti-malaria drug blocks proteotoxic stress response: anti-cancer implications. <i>Cell Cycle</i> , 2009 , 8, 3960-70	4.7	45
90	Cellular quiescence caused by the Mdm2 inhibitor nutlin-3A. <i>Cell Cycle</i> , 2009 , 8, 3777-81	4.7	62
89	9-Aminoacridine-based anticancer drugs target the PI3K/AKT/mTOR, NF-kappaB and p53 pathways. <i>Oncogene</i> , 2009 , 28, 1151-61	9.2	95
88	Small-molecule multidrug resistance-associated protein 1 inhibitor reversan increases the therapeutic index of chemotherapy in mouse models of neuroblastoma. <i>Cancer Research</i> , 2009 , 69, 6573-80	10.1	79
87	c-Myc depletion inhibits proliferation of human tumor cells at various stages of the cell cycle. <i>Oncogene</i> , 2008 , 27, 1905-15	9.2	115
86	Mycoplasma infection suppresses p53, activates NF-kappaB and cooperates with oncogenic Ras in rodent fibroblast transformation. <i>Oncogene</i> , 2008 , 27, 4521-31	9.2	59
85	Inhibition of human parainfluenza virus type 3 infection by novel small molecules. <i>Antiviral Research</i> , 2008 , 77, 83-94	10.8	13
84	An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. <i>Science</i> , 2008 , 320, 226-30	33.3	525
83	Quercetinase pirin makes poliovirus replication resistant to flavonoid quercetin. <i>DNA and Cell Biology</i> , 2008 , 27, 191-8	3.6	12
82	Functional genetic screening reveals the role of mitochondrial cytochrome b as a mediator of FAS-induced apoptosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 14453-8	11.5	18
81	Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 6302-7	11.5	144
80	In regard to Schuller et Al. (Int J Radiat Oncol Biol Phys 2007;68:205-210). <i>International Journal of Radiation Oncology Biology Physics</i> , 2008 , 70, 800-1; author reply 802-3	4	2

79	Different effect of proteasome inhibition on vesicular stomatitis virus and poliovirus replication. <i>PLoS ONE</i> , 2008 , 3, e1887	3.7	35
78	Quinacrine inhibits the epidermal dendritic cell migration initiating T cell-mediated skin inflammation. <i>European Journal of Immunology</i> , 2007 , 37, 2257-67	6.1	21
77	Prostate cancer cells tolerate a narrow range of androgen receptor expression and activity. <i>Prostate</i> , 2007 , 67, 1801-15	4.2	26
76	Dangerous habits of a security guard: the two faces of p53 as a drug target. <i>Human Molecular Genetics</i> , 2007 , 16 Spec No 1, R67-72	5.6	58
75	Small-molecule activators of RNase L with broad-spectrum antiviral activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007 , 104, 9585-90	11.5	70
74	p53 determines multidrug sensitivity of childhood neuroblastoma. <i>Cancer Research</i> , 2007 , 67, 10351-60	10.1	51
73	Keratinocyte growth factor (KGF) enhances postnatal T-cell development via enhancements in proliferation and function of thymic epithelial cells. <i>Blood</i> , 2007 , 109, 3803-11	2.2	161
72	Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3. <i>Cancer Research</i> , 2006 , 66, 3169-76	10.1	168
71	Inhibition of p53 response in tumor stroma improves efficacy of anticancer treatment by increasing antiangiogenic effects of chemotherapy and radiotherapy in mice. <i>Cancer Research</i> , 2006 , 66, 9356-61	10.1	49
70	A systematic search for downstream mediators of tumor suppressor function of p53 reveals a major role of BTG2 in suppression of Ras-induced transformation. <i>Genes and Development</i> , 2006 , 20, 236-52	12.6	113
69	Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation. <i>Nature Chemical Biology</i> , 2006 , 2, 474-9	11.7	292
68	Targeted disruption of the mouse ing1 locus results in reduced body size, hypersensitivity to radiation and elevated incidence of lymphomas. <i>Oncogene</i> , 2006 , 25, 857-66	9.2	60
67	p53 is a suppressor of inflammatory response in mice. <i>FASEB Journal</i> , 2005 , 19, 1030-2	0.9	187
66	Prospective therapeutic applications of p53 inhibitors. <i>Biochemical and Biophysical Research Communications</i> , 2005 , 331, 726-36	3.4	119
65	Sensitization of DNA damage-induced apoptosis by the proteasome inhibitor PS-341 is p53 dependent and involves target proteins 14-3-3sigma and survivin. <i>Molecular Cancer Therapeutics</i> , 2005 , 4, 1880-90	6.1	30
64	Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005 , 102, 17448-53	11.5	217
63	Down-regulation of p53 by double-stranded RNA modulates the antiviral response. <i>Journal of Virology</i> , 2005 , 79, 11105-14	6.6	55
62	Serologically defined colon cancer antigen 3 is necessary for the presentation of TNF receptor 1 on cell surface. <i>DNA and Cell Biology</i> , 2005 , 24, 777-85	3.6	15

61	Circadian sensitivity to the chemotherapeutic agent cyclophosphamide depends on the functional status of the CLOCK/BMAL1 transactivation complex. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005 , 102, 3407-12	11.5	201
60	Proteolytic cleavage of the p65-RelA subunit of NF-kappaB during poliovirus infection. <i>Journal of Biological Chemistry</i> , 2005 , 280, 24153-8	5.4	88
59	Poliovirus protein 3A binds and inactivates LIS1, causing block of membrane protein trafficking and deregulation of cell division. <i>Cell Cycle</i> , 2005 , 4, 1403-10	4.7	27
58	Therapeutic Strategies Based on Pharmacological Modulation of p53 Pathway 2005 , 225-242		
57	The ability of protein tyrosine phosphatase SHP-1 to suppress NFkappaB can be inhibited by dominant negative mutant of SIRPalph. <i>DNA and Cell Biology</i> , 2004 , 23, 175-82	3.6	15
56	Selection-subtraction approach (SSA): a universal genetic screening technique that enables negative selection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004 , 101, 9327-32	11.5	6
55	Secreted transforming growth factor beta2 activates NF-kappaB, blocks apoptosis, and is essential for the survival of some tumor cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004 , 101, 7112-7	11.5	85
54	Functional genetic screen for genes involved in senescence: role of Tid1, a homologue of the Drosophila tumor suppressor l(2)tid, in senescence and cell survival. <i>Molecular and Cellular Biology</i> , 2004 , 24, 10792-801	4.8	23
53	p53 pathway in renal cell carcinoma is repressed by a dominant mechanism. <i>Cancer Research</i> , 2004 , 64, 1951-8	10.1	84
52	Dual effect of p53 on radiation sensitivity in vivo: p53 promotes hematopoietic injury, but protects from gastro-intestinal syndrome in mice. <i>Oncogene</i> , 2004 , 23, 3265-71	9.2	191
51	Dominant negative form of signal-regulatory protein-alpha (SIRPalph /SHPS-1) inhibits tumor necrosis factor-mediated apoptosis by activation of NF-kappa B. <i>Journal of Biological Chemistry</i> , 2003 , 278, 3809-15	5.4	31
50	p53 inhibitor pifithrin alpha can suppress heat shock and glucocorticoid signaling pathways. <i>Journal of Biological Chemistry</i> , 2003 , 278, 15465-8	5.4	94
49	BMAL1-dependent circadian oscillation of nuclear CLOCK: posttranslational events induced by dimerization of transcriptional activators of the mammalian clock system. <i>Genes and Development</i> , 2003 , 17, 1921-32	12.6	195
48	Microarray analysis of p53-mediated transcription: multi-thousand piece puzzle or invitation to collective thinking. <i>Cancer Biology and Therapy</i> , 2003 , 2, 444-5	4.6	23
47	Genetic suppressor elements in the characterization and identification of tumor suppressor genes. <i>Methods in Molecular Biology</i> , 2003 , 222, 413-36	1.4	5
46	Isolation of p53 inhibitors by screening chemical libraries in cell-based readout system. <i>Methods in Molecular Biology</i> , 2003 , 223, 635-48	1.4	
45	Paradoxical role of apoptosis in tumor progression. <i>Journal of Cellular Biochemistry</i> , 2003 , 88, 128-37	4.7	39
44	Melanoma cells can tolerate high levels of transcriptionally active endogenous p53 but are sensitive to retrovirus-transduced p53. <i>Oncogene</i> , 2003 , 22, 4911-7	9.2	25

43	The role of p53 in determining sensitivity to radiotherapy. <i>Nature Reviews Cancer</i> , 2003 , 3, 117-29	31.3	456
42	Expression of prostate specific antigen (PSA) is negatively regulated by p53. <i>Oncogene</i> , 2002 , 21, 153-7	9.2	41
41	AKT2 is frequently upregulated in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival. <i>Oncogene</i> , 2002 , 21, 3532-40	9.2	119
40	Identification of a novel stress-responsive gene Hi95 involved in regulation of cell viability. <i>Oncogene</i> , 2002 , 21, 6017-31	9.2	280
39	Bisindolylmaleimide IX facilitates tumor necrosis factor receptor family-mediated cell death and acts as an inhibitor of transcription. <i>Journal of Biological Chemistry</i> , 2002 , 277, 33213-9	5.4	17
38	Apoptosis inhibitor as a suppressor of tumor progression: expression of Bcl-2 eliminates selective advantages for p53-deficient cells in the tumor. <i>Cancer Biology and Therapy</i> , 2002 , 1, 39-44	4.6	25
37	Cdk4 disruption renders primary mouse cells resistant to oncogenic transformation, leading to Arf/p53-independent senescence. <i>Genes and Development</i> , 2002 , 16, 2923-34	12.6	110
36	Falkor, a novel cell growth regulator isolated by a functional genetic screen. <i>Oncogene</i> , 2002 , 21, 6713-24	9.2	18
35	Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. <i>Oncogene</i> , 2001 , 20, 147-55	9.2	310
34	Functional analysis and intracellular localization of p53 modified by SUMO-1. <i>Oncogene</i> , 2001 , 20, 2587-99	9.2	111
33	The Bloom syndrome protein interacts and cooperates with p53 in regulation of transcription and cell growth control. <i>Oncogene</i> , 2001 , 20, 8276-80	9.2	35
32	Chemoprotection from p53-dependent apoptosis: potential clinical applications of the p53 inhibitors. <i>Biochemical Pharmacology</i> , 2001 , 62, 657-67	6	67
31	Poliovirus protein 3A inhibits tumor necrosis factor (TNF)-induced apoptosis by eliminating the TNF receptor from the cell surface. <i>Journal of Virology</i> , 2001 , 75, 10409-20	6.6	110
30	Differential association of products of alternative transcripts of the candidate tumor suppressor ING1 with the mSin3/HDAC1 transcriptional corepressor complex. <i>Journal of Biological Chemistry</i> , 2001 , 276, 8734-9	5.4	99
29	p53 Involvement in the control of murine hair follicle regression. <i>American Journal of Pathology</i> , 2001 , 158, 1913-9	5.8	65
28	Small molecules that dramatically alter multidrug resistance phenotype by modulating the substrate specificity of P-glycoprotein. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001 , 98, 14078-83	11.5	70
27	Pretreatment of the Cells With Brefeldin A and Cycloheximide Differently Regulates Fas and TNF Stimulated Apoptosis. <i>Scientific World Journal, The</i> , 2001 , 1, 40	2.2	
26	Expression of erbB receptors and their ligands in breast cancer: implications to biological behavior and therapeutic response. <i>Breast Disease</i> , 2000 , 11, 63-75	1.6	20

25	p53 is involved in tumor necrosis factor-alpha-induced apoptosis in the human prostatic carcinoma cell line LNCaP. <i>Oncogene</i> , 2000 , 19, 1959-68	9.2	63
24	Different impact of p53 and p21 on the radiation response of mouse tissues. <i>Oncogene</i> , 2000 , 19, 3791-8	9.2	101
23	Forward genetics in mammalian cells: functional approaches to gene discovery. <i>Human Molecular Genetics</i> , 1999 , 8, 1925-38	5.6	47
22	Structure and regulation of the mouse ing1 gene. Three alternative transcripts encode two phd finger proteins that have opposite effects on p53 function. <i>Journal of Biological Chemistry</i> , 1999 , 274, 32172-81	5.4	53
21	Generation of p53 suppressor peptide from the fragment of p53 protein. <i>Somatic Cell and Molecular Genetics</i> , 1999 , 25, 115-28		8
20	A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. <i>Science</i> , 1999 , 285, 1733-7	33.3	1079
19	Could p53 be a target for therapeutic suppression?. <i>Seminars in Cancer Biology</i> , 1998 , 8, 389-400	12.7	44
18	The candidate tumour suppressor p33ING1 cooperates with p53 in cell growth control. <i>Nature</i> , 1998 , 391, 295-8	50.4	255
17	Stress-induced secretion of growth inhibitors: a novel tumor suppressor function of p53. <i>Oncogene</i> , 1998 , 17, 1089-96	9.2	130
16	Cell transforming genes and tumor progression: in vivo unified secondary phenotypic cell changes. <i>International Journal of Cancer</i> , 1998 , 75, 277-83	7.5	32
15	Suppression of apoptosis by bcl-2 does not prevent p53-mediated control of experimental metastasis and anchorage dependence. <i>Oncogene</i> , 1997 , 15, 3007-12	9.2	17
14	Transgenic mice with p53-responsive lacZ: p53 activity varies dramatically during normal development and determines radiation and drug sensitivity in vivo. <i>EMBO Journal</i> , 1997 , 16, 1391-400	13	223
13	Localization of the candidate tumor suppressor gene ING1 to human chromosome 13q34. <i>Somatic Cell and Molecular Genetics</i> , 1997 , 23, 233-6		27
12	Applications of green fluorescent protein as a marker of retroviral vectors. <i>Somatic Cell and Molecular Genetics</i> , 1997 , 23, 325-40		23
11	Isolation of genetic suppressor elements (GSEs) from random fragment cDNA libraries in retroviral vectors. <i>Methods in Molecular Biology</i> , 1997 , 69, 221-40	1.4	15
10	Use of genetic suppressor elements to dissect distinct biological effects of separate p53 domains. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1996 , 93, 10309-14	11.5	153
9	Involvement of MDR1 P-glycoprotein in multifactorial resistance to methotrexate. <i>International Journal of Cancer</i> , 1996 , 65, 613-9	7.5	62
8	Suppression of the novel growth inhibitor p33ING1 promotes neoplastic transformation. <i>Nature Genetics</i> , 1996 , 14, 415-20	36.3	254

7	Involvement of MDR1 P-glycoprotein in multifactorial resistance to methotrexate 1996 , 65, 613		1
6	Cloning mammalian genes by expression selection of genetic suppressor elements: association of kinesin with drug resistance and cell immortalization. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1994 , 91, 3744-8	11.5	120
5	Isolation of genetic suppressor elements, inducing resistance to topoisomerase II-interactive cytotoxic drugs, from human topoisomerase II cDNA. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1993 , 90, 3231-5	11.5	119
4	Long terminal repeats of dwarf hamster endogenous retrovirus are highly diverged and do not maintain efficient transcription. <i>Virology</i> , 1991 , 181, 367-70	3.6	1
3	Distribution of mouse mammary tumor virus-related sequences does not correlate with the taxonomic position of their hosts. <i>Virus Genes</i> , 1990 , 4, 85-92	2.3	3
2	Quantitative Characterization of Biological Age and Frailty Based on Locomotor Activity Records		3
1	Identification of a blood test-based biomarker of aging through deep learning of aging trajectories in large phenotypic datasets of mice		3